12 results about "In vitro test" patented technology

The disclosure relates to formulations and methods for the in vitro testing of ocular irritants. It was discovered that adding an antioxidant formulation to in vitro ocular irritation tests, including for example, a biochemical ocular irritation test, a reconstituted human corneal epithelium (RhCE) ocular irritation test and an excised eye depth of injury (Dol) test, substantially reduces the rate of false positives without diminishing test sensitivity, resulting in more accurately predicting ocular irritancy of test substances. More particularly, the disclosed method employs relatively high physiologic concentrations of one or more antioxidants that are normally present in tears. In a variation, much higher concentrations of one or more antioxidants may provide protection against in vivo exposure to ocular irritants.

This invention discloses a semi-sandwich structured ruthenium triphenylphosphine dithiocarboxylic acid complex with a simple preparation process and its applications. The complex has the structure shown in Figure (I), with the central ruthenium and... η 5 - Coordination with cyclopentadiene, triphenylphosphine, and dithiocarboxylic acid derivatives, wherein the dithiocarboxylic acid ligands are selected from ethyl xanthic acid, isopropyl xanthic acid, ... N,N Diethyldithiocarbamic acid, morpholine dithiocarbamic acid, and carbazole dithiocarbamic acid. This invention employs a simple one-step method of room temperature preparation and recrystallization purification using a ruthenium precursor and dithiocarbamic acid ligand. This method offers advantages such as readily available raw materials, mild reaction conditions, simple post-processing, and high yield. In vitro tests show that the complexes exhibit excellent anti-proliferative activity against non-small cell lung cancer A549 cells, significantly superior to cisplatin. The complexes demonstrate activity by reducing mitochondrial membrane potential, inducing intracellular reactive oxygen species accumulation, and arresting the cell cycle (G1 phase), leading to late apoptosis in A549 cells.

The present application relates to the technical field of veterinary medicine preparation, and particularly relates to a water-soluble medicine gastro-resistant and enteric-coated granule, a preparation method and application thereof, the coated granule comprising: an inner core of at least one water-soluble medicine active ingredient, a coating layer coated outside the inner core; and the coating layer is formed by a composite coating material of hydrogenated palm oil and lipophilic hydrophobic nano active light calcium carbonate. The present application has the advantages that the nano calcium carbonate is used to form pores in the true stomach by acid reaction and to produce gas by saponification with fatty acids in the intestinal tract, so that the water-soluble medicine is efficiently protected in the rumen and rapidly and completely released in the intestinal tract. In vitro tests show that the effective release rate can reach more than 79%, which is significantly better than the traditional coating, and has a broad clinical application prospect.

This invention relates to the field of computational toxicology, and in particular to a precise method for comparing the consistency of animal and non-animal toxicity evaluation results. This method acquires in vivo baseline data from animals and in vitro test data from non-animals. It employs a dynamic time warping algorithm and radial basis function kernel function to construct correction coefficients and perform equivalent mapping to generate a converted sequence. Based on a binary classification mapping of toxicity thresholds, a confusion matrix is ​​constructed to calculate sensitivity, specificity, and predicted values. Each indicator is treated as an independent source of evidence, and the Mahalanobis distance is calculated using the covariance matrix to generate a basic probability allocation function. The D-S evidence theory combination rule is applied for fusion, and a secondary factor allocation is introduced when there is conflict. Finally, the result is compared with a preset threshold to determine the feasibility of substitution. This invention adaptively eliminates the nonlinear misalignment difference between in vivo and in vitro dose responses, providing an objective quantitative judgment standard for toxicological substitution verification.

The present disclosure provides a system, device, control method and storage medium for simulating physical characteristics of blood vessels. The method for simulating physical characteristics of blood vessels comprises determining blood vessel types of a lesion to be studied, collecting clinical medical data of the lesion blood vessels, performing isolated modeling on each blood vessel branch, setting initial reference values of the model, connecting the blood vessel model and the device for simulating physical characteristics of blood vessels to an in-vitro test device, operating the in-vitro test device based on the initial reference values, and calculating blood vessel resistance, compliance and test temperature in the blood vessel model in real time according to sensor collected data, and calculating differences between target values and corresponding measured values. The in-vitro test device is adjusted through a simulated neural feedback mechanism and a direct coordination mechanism of each blood vessel branch until the differences between the target values and the corresponding measured values meet predetermined conditions.

The application provides a use of a banana tissue endogenous hormone zeatin in resisting banana wilt, and belongs to the technical field of plant protection. The banana tissue endogenous hormone is zeatin, and experiments prove that in vitro tests (tissue culture bottles and greenhouses) of the zeatin or lutein show that the zeatin can effectively inhibit the growth of TR4 mycelium, exhibits good anti-banana wilt fungus activity, has a significant prevention and control effect on the banana wilt fungus (TR4), and does not affect the growth of seedlings. The application provides a new idea and method for preventing and controlling TR4, and lays a foundation for in-depth exploration of the prevention and control of the banana wilt disease TR4.

The present application relates to the technical field of probiotic preparation, and particularly relates to a gastroenteric probiotic granule and a preparation method and application thereof, the coated granule comprises: a probiotic core material, and a coating layer coated outside the core material; the coating layer is formed by a composite coating material of hydrogenated palm oil and stearic acid surface modified nano active calcium carbonate, wherein the stearic acid surface modified nano active calcium carbonate accounts for 50% to 60% of the total mass of the composite coating material, and the weight ratio of the coating layer to the core material is 20% to 25%. The present application utilizes hydrogenated palm oil to form a hydrophobic physical barrier, and simultaneously utilizes nano calcium carbonate to slowly neutralize acidity in gastric acid, generate bubbles to form a microenvironment buffer, and realize a dual synergistic protection mechanism of physical barrier and chemical buffer. In vitro tests show that the probiotic granule prepared by the present application has a survival rate of greater than or equal to 90% after being treated in artificial gastric juice for 2 hours, and a release rate of greater than or equal to 93% after being treated in artificial intestinal juice for 2 hours, which is significantly better than traditional coating technology, and has a broad industrial application prospect.

The present invention relates to methods for producing an artificial basement membrane comprising a fiber mesh, artificial basement membranes comprising a fiber mesh, in particular produced by means of the method according to the invention, as well as in vitro test systems, cell culture systems, filtration systems and organ systems comprising at least one artificial basement membrane of the present invention.

This invention discloses a systemic circulation venous simulation system, comprising a right ventricular simulation component, an arterial compliance simulation component, a venous vessel module, a damping module, a throttling valve, a collapsible venous segment, a venous compliance simulation component, a right atrial simulation component, a drive module, and a data acquisition module. The right ventricular simulation component simulates the pumping function of the right ventricle; the arterial compliance simulation component simulates the elastic energy storage characteristics of the arterial system; the venous vessel module includes a collecting chamber, a superior vena cava return vessel, an inferior vena cava return vessel, and a vena cava confluence conduit; the collapsible venous segment prevents excessive negative pressure in the venous system; the venous compliance simulation component reduces the impact of right atrial pressure fluctuations on the venous vessels; and the right atrial simulation component simulates the right atrial filling state through internal volume changes. This simulation system can be used for in vitro testing of vena cava intervention devices.

This invention proposes an in vitro testing device for the aortic valve and ascending aorta, comprising a chamber system, a drive system, a circuit system, a chamber auxiliary system, a control system, and a particle image velocimetry system. Based on patient medical images, this device constructs a 1:1 personalized aortic valve and ascending aorta vascular model, realistically simulating an individualized hemodynamic environment through closed-loop pulsatile flow circulation. It can rapidly and quantitatively acquire complex functional parameters such as blood flow velocity, pressure, wall shear force, and relative particle residence time, overcoming the limitations of traditional imaging providing only morphological data and CFD simulation relying on ideal assumptions. Simultaneously, it can be used for individualized in vitro testing of artificial aortic valves, evaluating their performance in specific anatomical structures, significantly improving the accuracy of preoperative planning, postoperative prediction, and device development. This device has advantages such as high physiological fidelity, high testing efficiency, and strong result repeatability, making it suitable for precision cardiovascular diagnosis and treatment and evaluation of implantable interventional devices.

The application relates to the field of biological medicine, and particularly discloses application of RNA pseudouridine modification in preparation of an acute myeloid leukemia in vitro detection product. The application takes the pseudouridine modification level of a specific gene-derived RNA molecule as an inspection index, reflects the molecular changes related to acute myeloid leukemia from the aspect of epitranscription, helps to improve the accuracy of risk assessment of acute myeloid leukemia, and has sensitivity and specificity in distinguishing acute myeloid leukemia and normal controls in terms of the pseudouridine modification level of the RNA molecule corresponding to any one of the PDE3A gene, the DPP9 gene, the SNORD59A gene, the FP236383.1 gene, the SNORD14C gene and the RNU2-6P gene. The application can be applied to the detection of blood or bone marrow and other samples outside the body, the sampling mode is simple, has good accessibility and popularization value, and is favorable for realizing early screening and risk stratification of acute myeloid leukemia.

The present application relates to an antibacterial product based on olive leaf extract, belonging to the technical field of antibacterial care. The product is based on olive leaf extract rich in polyphenol active ingredients, combined with bacteriostatic polypeptides derived from Xenopus laevis as the core active component, to achieve synergistic antibacterial effect. Studies have shown that the combination has rapid and strong inhibitory and killing ability on common pathogenic microorganisms such as Staphylococcus aureus and Candida albicans, and is significantly better than single component. In vitro test results show that the product can achieve strong bacteriostatic and bactericidal effect in a short time, and has certain sustained bacteriostatic ability. Compared with traditional antibiotics or single plant extract, the present application improves the antibacterial efficiency and reduces the risk of drug resistance through the synergistic mechanism of "natural plant matrix + functional polypeptide", and has good safety and microecological friendliness, and is suitable for daily care and infection protection of female reproductive system.